Overcoming Challenges of Implementing Closed System Transfer Device Clinical In-Use Compatibility Testing for Drug Development of Antibody Drug Conjugates.

Closed System Transfer Devices (CSTD) are a supplemental engineering control designed to reduce occupational exposure of hazardous drugs and are currently implemented in accordance to evolving regulations. Due to the novelty and complexity of these devices and their importance in clinical in-use testing, here we evaluated FDA approved CSTD, assessing product quality through stability indicating assays to determine any drug product incompatibilities. Six devices were used in a simulated compounding and administration of a late phase IgG1 Antibody Drug Conjugate (ADC) and the resulting samples were analyzed for visible and subvisible particle counts by light obscuration and micro-flow imaging, physical stability by size exclusion chromatography, and biological activities by relative potency. Potential challenges included improper fit of CSTD components, loss of product to void volume, and material incompatibility. Results showed compatibility of the ADC with the six CSTD evaluated. One CSTD introduced subvisible particles into the ADC during compounding that were identified through morphological assessment as silicone oil. This study highlights the importance of clinical in use testing with new devices and proposes strategies to mitigate the risk of drug product incompatibility with CSTD.

[1]  L. Power,et al.  ASHP Guidelines on Handling Hazardous Drugs , 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[2]  Steven Kozlowski,et al.  Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.

[3]  S. Kumagai,et al.  Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. , 2009, The Annals of occupational hygiene.

[4]  Lennart Johansson,et al.  Spill and leakage using a drug preparation system based on double-filter technology. , 2008, The Annals of occupational hygiene.

[5]  M. Okuda,et al.  Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital , 2013, SpringerPlus.

[6]  R. Torres,et al.  Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice. , 2016, Journal of pharmaceutical sciences.

[7]  P. Bonnabry,et al.  Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study , 2016, PloS one.

[8]  A. Turner,et al.  Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[9]  C. Ammann,et al.  Stability Studies Needed to Define the Handling and Transport Conditions of Sensitive Pharmaceutical or Biotechnological Products , 2011, AAPS PharmSciTech.

[10]  A. Al-jedai,et al.  Comparison of closed system transfer devices for turnaround time and ease of use , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[11]  M. Slawson,et al.  Workplace Contamination with Antineoplastic Agents in a New Cancer Hospital Using a Closed-System Drug Transfer Device , 2007 .

[12]  L. Tyler,et al.  Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[13]  Kiichi Fukui,et al.  Effects of Syringe Material and Silicone Oil Lubrication on the Stability of Pharmaceutical Proteins , 2014, Journal of pharmaceutical sciences.

[14]  L. Power,et al.  Multicenter evaluation of a new closed system drug‐transfer device in reducing surface contamination by antineoplastic hazardous drugs , 2018, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[15]  K. Gurusamy,et al.  Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff. , 2018, The Cochrane database of systematic reviews.

[16]  M. Feuilloley,et al.  Container-content compatibility studies: a pharmaceutical team's integrated approach. , 2009, PDA journal of pharmaceutical science and technology.

[17]  Clifford J. Mallett,et al.  Treatment time, ease of use and cost associated with use of Equashield™, PhaSeal®, or no closed system transfer device for administration of cancer chemotherapy to a dog model† , 2017, Veterinary and comparative oncology.

[18]  D. K. Sharma,et al.  Micro-Flow Imaging: Flow Microscopy Applied to Sub-visible Particulate Analysis in Protein Formulations , 2010, The AAPS Journal.

[19]  P. Sessink,et al.  Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device , 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[20]  P. Sessink,et al.  Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents , 2013, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[21]  D. Lebel,et al.  Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device , 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[22]  S. Singh,et al.  An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. , 2010, Journal of pharmaceutical sciences.

[23]  H. Chan,et al.  Cost Analysis of Using a Closed-System Transfer Device (CSTD) for Antineoplastic Drug preparation in a Malaysian Government-Funded Hospital , 2016, Asian Pacific journal of cancer prevention : APJCP.

[24]  Stephen F Eckel,et al.  Application of the 2015 proposed NIOSH vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[25]  E. Meade Use of closed-system drug transfer devices in the handling and administration of MABs. , 2015, British journal of nursing.